THOMAS SCHALLER: Open Payments
NPI 1578330882 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$450 in 20 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $773 · 2025 $450
Food & beverage: $450
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $118 |
| Bausch Health US, LLC | 2 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Neos Therapeutics, LP | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $31 |
| Lundbeck LLC | 1 | $31 |
| Alkermes, Inc. | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Tris Pharma Inc | 1 | $22 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $19 |
Products named: REXULTI, APLENZIN, CAPLYTA, Adzenys XR-ODT, AUSTEDO XR, ARISTADA, FANAPT, Dyanavel XR.
Industry payments across TX — which companies pay providers there.
